
Sign up to save your podcasts
Or


In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib?
By Bernard Marini, Anthony Perissinotti, et al.4.5
3030 ratings
In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib?

38,475 Listeners

25,802 Listeners

87,131 Listeners

111,848 Listeners

56,523 Listeners

187 Listeners

10,215 Listeners

7,222 Listeners

52 Listeners

8 Listeners

15,849 Listeners

10,682 Listeners

51 Listeners

192 Listeners

615 Listeners